Scanogen square logo


pippeting hands background


Scanogen is a biotechnology and medical device start-up company founded in 2011. The company has developed  Single Molecule Scanning, a proprietary technology for rapid and ultra-sensitive detection of biomolecules. Scanogen is using this technology to develop point of care tests that will improve health care by providing easy and inexpensive access to the genetic information present in patient samples. The company has received NIH grants totalling over $6 million to develop its diagnostic assays. Scanogen is focused on three areas: Point-of-care detection of infectious diseases, blood infection detection and early cancer detection.

The company is located in Baltimore, Maryland. This is a privileged location to interact with some of the best biomedical researchers in the country at Johns Hopkins University and with  government agencies in Washington D.C (FDA, NIH, NIST).


Al Celedon

Thomas Borgoyn
Alfredo (Al) Celedon, CEO

Thomas Borgoyn, CTO

Al discovered a novel method to detect biomolecules and encouraged by the potential of the new technology founded Scanogen. Al is leading the development of Single Molecule Scanning tests for the detection of infectious diseases and early diagnosis of cancer. He has established collaborations with researchers at the Johns Hopkins School of Medicine and has filed patents for 5 inventions. Before funding Scanogen, Al was a visiting professor at the Institute for BioNanotechnology at Johns Hopkins. Al holds a Ph.D from Johns Hopkins University and a Masters from University of California, Los Angeles.
Tom is the former Vice President of Engineering and Software at Becton Dickinson (BD). During his 37 years of experience at BD, he led the development of several diagnostic systems which are still successful products of BD. He led development of automated instruments and disposables cartridges, from product design to manufacturing and quality control. He was the Program Director for the development, implementation and successful market introduction of the Phoenix System. He was also responsible for the development and troubleshooting of the production plant for the Phoenix disposable cartridge. He ensured that products met all regulatory, quality, manufacturability and user requirements and introduced Design for Six Sigma methodologies into the R&D organization. He participated in the R&D Management Council for BD, where I provided guidance on strategic decisions regarding R&D investments direction.


Greg Meehan

Gregory Meehan

Joseph M. Migliara

Greg was an executive at Becton Dickinson for 30 years with leadership roles at BD Diagnostic Systems division. He was Vice President of Product Planning, Vice President of Diagnostic Systems and General Manager among other positions. As VP of Product Planning, he developed a novel development funnel for the molecular business. He refined a methodology to predict opportunities in new markets and identify ways to reinvigorate established business. As VP of Diagnostic Systems, he diversified BD diagnostic products with high value differentiated diagnostics across the full range of infectious disease testing including respiratory, enteric, and viral applications. As General Manager, he led U.S Sales, Marketing, Technical Service and Customer Service (350 employees). Exceeded divisional revenue and goals for $375 MM clinical and industrial businesses for 3 consecutive years. Launched new platform exceeding sales records. Led regional team in implementing U.S molecular sales and marketing strategy achieving $50 MM growth over 4 years. He developed and implemented pricing, marketing, and sales strategies and tactics to achieve or exceed revenue and gross profit goals for product portfolio, resulting in record revenues and gross profit growth.
Joe is an experienced CEO with experience in the diagnostic industry. He developed and implemented strategies to finance, staff and commercialize medical and diagnostic products for both private and public enterprises. He co-founded and sold two healthcare market analysis companies. He also participated at the board and senior management levels in sale of two healthcare public companies with a total value of $2 billion and spearheaded acquisition of domestic and foreign companies. He was the lead independent director of the molecular diagnostic company Digene Corp. which was sold to QIAGEN in 2007 for $1.4 billion. He was an investor and director of XLHealth Corporation, a Medicare Advantage insurer targeting diabetic and CHF enrollees. He served as president of the Biomedical Marketing Association. Joe serves as trustee of Northwest Hospital in Randallstown, Maryland. Joe holds a bachelor’s degree in economics from The Wharton School at the University of Pennsylvania and an MBA. from Fairleigh Dickinson University.

Arthur Colvin
Antony Newton
Arthur (Skip) Colvin

Antony Newton
Skip has over 35 years of experience in biotechnology and medical device product creation and development. Skip began his career at the startup of Life Technologies, then founded and served as President of Cerex Inc. Most recently Skip cofounded Senseonics, and is the inventor of the company's core technology. He has created and led the development of more than 40 products for the biotechnology, food processing, and medical device industries and holds nearly 70 issued and pending US patents not including international counterparts. He holds a BS in Biochemistry from the Virginia Polytechnic Institute with graduate studies in Biochemical Engineering at the University of Maryland and the Johns Hopkins University (APL)
Antony is a biotechnology industry veteran with over 25 years’ experience at companies including Amersham International (GE Life Sciences), Sigma- Aldrich and as a Vice President in Genzyme Oncology. Antony was part of a team that built the Genzyme Oncology business from conception to a ~$1BN commercial business and was responsible for a range of roles in program and portfolio management, alliances and collaborations.  Antony has a M.Sc. from Brunel University, London and a PG Dip (DMS) from Anglia Ruskin University, Cambridge.


William Bishai, M.D., Ph.D.  Co-Director of the Center for TB research at Johns Hopkins University School of Medicine.

Karen Carroll, M.D. Director of the Division of Medical Microbiology at Johns Hopkins University School of Medicine.

Michael Goggins, M.D. Director of the Pancreatic Cancer Early Detection Laboratory at Johns Hopkins University School of Medicine.

Richard Rothman, M.D., Ph.D.  Vice-Chair of Research, Emergency Medicine at Johns Hopkins University School of Medicine.


Point-of-care infection detection
Scanogen is developing a point-of-care platform for rapid and inexpensive detection of infectious diseases.  The test will make molecular diagnostics possible in small clinics, pharmacies and rural areas. A rapid TB test is under development in collaboration with Dr. William Bishai and Dr. Nikki Parrish.

Blood infection detection
Scanogen is developing diagnostic tests for the detection of pathogen and drug resistance in collaboration with Dr. Richard Rothman and Dr. Karen Carroll.

Early cancer detection
Scanogen is developing a test to screen for pancreatic cancer before symptoms appear, by detecting the presence of mutated DNA in blood and urine. The test is being developed in collaboration with Dr. Michael Goggins 


Scanogen has been funded with grants from the National Institute of Allergy and Infectious Diseases, the National Human Genome Research Institute, and the National Cancer Institute through its program Innovative Molecular Analysis Technologies.

IMAT logo
NHGRI logo
NCI logo
home link
2019 Scanogen Inc.

3102 Lord Baltimore Dr., Suite 214, Baltimore, MD, 21244 |